tbuckley/cabot-search huggingface dataset:
UTILIDAD DE LA PANCROMOENDOSCOPIA CON ÍNDIGO CARMÍN PARA EL SEGUIMIENTO DE LOS PACIENTES CON SÍNDROME DE POLIPOSIS SERRADA
Authors: J López Vicente, D Rodriguez Alcalde, L Hernández Villalba, F Riu Pons, P Vega Villaamil, I Salces Franco, J Santiago García, M Bustamante Balen, M López-Cerón Pinilla, M Domínguez Antonaya
Journal: Endoscopy (2016)

Introducción: El Síndrome de Poliposis Serrada (SPS) es una condición de riesgo de cáncer colorrectal. La pancromoendoscopia con índigo carmín ha demostrado mejorar la detección de lesiones colónicas, pero se desconoce su utilidad en el SPS.
TCT-581 Plaque redistribution after stenting: data from NIRS-IVUS imaging
Authors: Tomasz Roleder, Magdalena Dobrolińska, Elzbieta Pociask, Wojciech Wanha, Grzegorz Smolka, Tomasz Bochenek, Wojciech Walkowicz, Mariusz Lebek, Radoslaw Parma, Andrzej Ochala, Zbigniew Gasior, Michal Tendera, Wojtek Wojakowski
Journal: Journal of the American College of Cardiology (2016)
TCT-135 Increased circulating plasma-free hemoglobin levels, not lactate dehydrogenase, levels identify hemolysis among patients with cardiogenic shock treated with an Impella micro-axial flow catheter
Authors: Michele Esposito, Ryan O'Kelly, Nima Aghili, Shiva Annamalai, Anas Hamadeh, Michael Kiernan, Amanda Vest, David DeNofrio, Navin Kapur
Journal: Journal of the American College of Cardiology (2016)
TCT-413 Feasibility of direct scaffolding in acute coronary syndromes patients with relatively simple non-calcified culprit lesions. A pooled analysis of BVS STEMI First and BVS Expand Studies
Authors: Mariusz Tomaniak, Jiang Ming Fam, Cordula Felix, Robert-Jan van Geuns, Nicolas Van Mieghem, Evelyn Regar, Joost Daemen, Felix Zijlstra, Roberto Diletti
Journal: Journal of the American College of Cardiology (2016)
TCT-300 Dyspnea Among Patients with Chronic Total Occlusions Selected for Percutaneous Coronary Intervention: Prevalence and Predictors of Improvement
Authors: Mohammed Qintar, James Sapontis, J. Aaron Grantham, William Lombardi, Dimitri Karmpaliotis, Jeffrey Moses, Kensey Gosch, John Spertus, Adam Salisbury, Suzanne Arnold
Journal: Journal of the American College of Cardiology (2016)
Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study.
Authors: Sungmin Park, Sekyung Lee, Soo Youn Bae, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Juhee Cho
Journal: Journal of Clinical Oncology (2016)

195 Background: Breast cancer diagnosis and treatment often produce stress in patients.Anxiety is one of the most prevalent psychological symptoms perceived by breast cancer patients. This study aims to evaluate the temporal patterns of anxiety and find factors associated with persistent anxiety during breast cancer treatment. Methods: This is prospective cohort study. Between July 2010 and July 2011, we recruited patients with non-metastatic breast cancer who were expected to receive adjuvant chemotherapy (N = 411) from two cancer hospitals in Seoul, Korea. Trained researchers interviewed participants and the patients also completed questionnaires on quality of life at enrollment (before surgery), 2 weeks, 3 months, 6 months and 12 months post-surgery. Anxiety was measured using the Hospital Anxiety and Depression Scale (HADS). Borderline and abnormal levels of HADS scores were classified into the abnormal group for comparison purposes. Results: The mean age of the participants was 46.4 (±7.9) years. Preoperatively, 44.5 % (183/411) of the patients showed abnormal anxiety. The proportion of the subnormal anxiety group significantly decreased after surgery (P &lt; .01) and this phenomenon continued until the 12 month follow-up point. Patients experienced renewed anxiety at 12 months when the main adjuvant therapies were finished. Socioeconomic factors were not associated with persistent anxiety. Pain, breast, and arm symptoms were significantly higher in the persistently abnormal group, especially at postoperative 6months and 12months. Conclusions: Anxiety disorder was common in patients who were diagnosed with breast cancer (44.5%). Surgery was a major relieving factor of anxiety, and patients who finished their main adjuvant treatment experienced renewed anxiety. Surgeons should be the main detectors and care-givers with respect to psychological distress in breast cancer patients. To reduce persistent anxiety, caring for the patient’s physical symptoms is important.
TCT-755 Comparison Of Clinical Profile And Outcomes After Transcatheter Aortic Valve Replacement In Nonagenarians Versus Younger Patients
Authors: Rafael Alexandre Meneguz-Moreno, Alfredo Nunes Ferreira Neto, Auristela Ramos, Dimytri Siqueira, David Le Bihan, Rodrigo Barretto, Adriana Moreira, Alexandre Abizaid, Amanda Sousa, J. Eduardo Sousa
Journal: Journal of the American College of Cardiology (2016)
Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results.
Authors: Julia Bohlius, Jayne Wilson, Sue Bayliss, Benjamin Djulbegovic, Chris Hyde, Sven Trelle, Olaf Weingart, Susan Brunskill, Josie Sandercock, Jerome Seidenfeld, Margaret Piper, Simon Langensiepen, Guido Schwarzer, Charles Bennett, Andreas Engert
Journal: Blood (2005)
TCT-185 Influence of total ischemic time on clinical outcomes and efficacy of manual thrombus aspiration during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Analysis from the POST trial
Authors: Ji-Hoon Jang, Dong-Kie Kim, Pil Sang Song, Doo-Il Kim, Joo-Yong Hahn
Journal: Journal of the American College of Cardiology (2016)
GMC warns of “state of unease” in medical profession
Authors: Abi Rimmer
Journal: BMJ (2016)

A state of unease exists in the medical profession, as well as a dangerous level of alienation among junior doctors, the General Medical Council (GMC) has warned.

The GMC published its sixth annual report on the state of medical education and practice in the United Kingdom on Thursday 27 October, which showed that doctors and NHS services were under increasing pressure.1

Commenting on the report, Terence Stephenson, GMC chair, said, “There is a state of unease within the medical profession across the …
Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma
Authors: Julie M Vose, Fausto R. Loberiza, R. Gregory Bociek, Philip Bierman, James O. Armitage
Journal: Blood (2012)
TCT-756 Transcatheter versus Surgical Aortic-Valve Replacement in Intermediate-Risk Patients: Evidence from a Meta-analysis
Authors: Partha Sardar, Amartya Kundu, Saurav Chatterjee, Dmitriy Feldman, Theophilus Owan, Ramez Nairooz, Ted Feldman, J. Dawn Abbott, Sammy Elmariah
Journal: Journal of the American College of Cardiology (2016)
Hypoxia-inducible protein 2 (HIG2) as a new biomarker of ovarian clear cell adenocarcinoma
Authors: S. Nishimura, H. Tsuda, K. Ito, T. Kita, Y. Terai, T. Sudo, T. Jobo, J. Kigawa, T. Sugiyama, N. Yaegashi
Journal: Journal of Clinical Oncology (2007)

16001 Background: Epithelial ovarian cancer (EOC) can be subclassified into five major histologic types (Serous(SC), Mucinous(MC), Endometrioid(EC), Clear cell(CC), Undifferentiated (UC)). Among them, CC generally has a poor response to combination chemotherapy and its overall prognosis is poorer, as compared with other histologic types. In previous reports, we compared gene expression profiles in CC and SC using cDNA microarrays and suggested that HIG2 gene might be a new biomarker for CC (Clin Cancer Res, 2005). In this study, we generated a polyclonal antibody for HIG2 and further validated the expression of HIG2 in EOC. In addition, HIG2 expression was evaluated in CC derived from endometrium(EMCC) and kidney(KDCC). Methods: Formalin-fixed surgical samples from 254 EOC, 17 EMCC and 29 KDCC patients were included in this study. HIG2 expression was investigated by immunohistochemistry. HIG2 cytoplasmic staining were divided into positive or negative. Results: Histologic types and stages of EOC were as followed: (SC: 51; MC: 25; EC: 31; CC: 130; UC: 17) and (I: 96; II: 37; III: 100; IV: 21). In EOC, 175 of 254(69%) cases had HIG2 expression. The relationship between HIG2 expression and histologic types was shown in table . The positive rate of HIG2 in CC was significantly higher than other histologic types in EOC. However, there is no significant correlation between HIG2 expression and stages or grades. In addition, both CC of the ovary and endometrium showed significantly higher levels of HIG2 expression compared to those of CC of the kidney. Conclusions: HIG2 expression is a new biomarker for CC. [Table: see text] No significant financial relationships to disclose.
TCT-308 Impact of Race and Ethnicity on Technical and In-Hospital Outcomes Following Chronic Total Occlusions Percutaneous Coronary Intervention.
Authors: Erica Resendes, Dimitri Karmpaliotis, Khaldoon Alaswad, Farouc Jaffer, Robert Yeh, R. Michael Wyman, Mitul Patel, John Bahadorani, William Lombardi, J. Aaron Grantham, David Kandzari, Nicholas Lembo, Jeffrey Moses, Ajay Kirtane, Catalin Toma, Anthony Doing, James Choi, Barry Uretsky, Aya Alame, Judit Karacsonyi, Barbara Anna Danek, Michael Smith, Aris Karatasakis, Bavana Rangan, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2016)
TCT-737 Baseline growth differentiation factor 15 (GDF15) is an independent predictor of reverse left atrial remodeling and mortality at 1-year following Transcatheter Aortic Valve Replacement
Authors: Juyong Kim, Yukari Kobayashi, Daniel Brenner, Kegan Moneghetti, Ryan O'Malley, Catherine Dao, Thu Vu, Ingela Schnittger, David Liang, Joseph Wu, Michael Fischbein, Anson Lee, D. Craig Miller, Alan Yeung, Francois Haddad, William Fearon
Journal: Journal of the American College of Cardiology (2016)
Carboplatin dosing by predictive formulae and factors related to its myelosuppressive toxicity
Authors: S. J. Ayirookuzhi, J. McLarty, R. Mansour, G. M. Mills
Journal: Journal of Clinical Oncology (2009)

e19101 Background: Carboplatin is a commonly used drug in stage III/IV non-small cell lung cancer (NSCLC). Its dose in typically calculated with the Calvert equation that uses the glomerular filtration rate (GFR) from various predictive formulae such as MDRD, Cockroft-Gault, Jeliffe and Wright as well as the targeted area under the curve (AUC) for carboplatin. Myelosuppression is a common toxicity of carboplatin and this study aimed to assess the relationship between dosing and toxicity as well as if there would be any significant difference in dosing based on calculation of GFR from the above formulae in our patient population. Methods: Data from patients with Stage III and IV NSCLC seen between 1/1/99 to 12/31/2007 were analyzed. Patients who received concurrent radiation, who died before the first cycle was completed, as well as patients with missing lab values were excluded. Only the first cycle of the carboplatin based regime was used for analysis with nadir platelets, hemoglobin and wbc's used as endpoints. SPSS software was used for statistical analysis including Pearson correlation, ANCOVA, independent t-tests as well as multivariate linear regression models. Results: Of the 216 patients initially abstracted for analysis only 132 patients were analyzable. Demographically 71 were Caucasian and rest were African-American while 92 were male. The carboplatin dose calculated from all four formulae were highly correlated (p &lt; 0.0001). The drop in the three cell counts were correlated to each other (p&lt; 0.05), particularly the drop in platelet count with other two cell counts. The correlation between the drop in wbc and drop in hemoglobin approached significance (p=0.075). The nadir wbc was significantly associated with BSA (p=0.004), wbc level at baseline (p&lt; 0.000) and approached significance for carboplatin dose (p=0.059) by ANCOVA analysis, while significance was not reached for nadir platelets or nadir hemoglobin. Conclusions: The different predictive equations resulted in similar doses of carboplatin that were statistically significant. BSA correlated significantly with myelosuppression while carboplatin dose only approached significance. No significant financial relationships to disclose.
TCT-567 In Vivo Reconstruction of Bioresorbable Stents and Its Impact on Computation of Shear Stress
Authors: Yingguang Li, Niels Holm, Zhenyu Fei, Jouke Dijkstra, Pieter Kitslaar, Emil Holck, Evald Christiansen, Johan Reiber, Shengxian Tu
Journal: Journal of the American College of Cardiology (2016)
TCT-464 The Influence of Diabetes Mellitus on Clinical Outcomes Following Implantation of a novel abluminal coated sirolimus eluting stent that enhances drug delivery through the delivery balloon: Insights from en-ABL e-Registry
Authors: Luca Testa, Sameer Dani, Devang Maheshchandra Desai, Rashmit Pandya, Pritesh Parekh
Journal: Journal of the American College of Cardiology (2016)
Use of Sex-Specific Clinical and Exercise Risk Scores to Identify Patients at Increased Risk for All-Cause Mortality
Authors: Paul C. Cremer, Yuping Wu, Haitham M. Ahmed, Lee M. Pierson, Danielle M. Brennan, Mouaz H. Al-Mallah, Clinton A. Brawner, Jonathan K. Ehrman, Steven J. Keteyian, Roger S. Blumenthal, Michael J. Blaha, Leslie Cho
Journal: JAMA Cardiology (2016)

Risk assessment tools for exercise treadmill testing may have limited external validity. Cardiovascular mortality has decreased in recent decades, and women have been underrepresented in prior cohorts.To determine whether exercise and clinical variables are associated with differential mortality outcomes in men and women and to assess whether sex-specific risk scores better estimate all-cause mortality.This retrospective cohort study included 59 877 patients seen at the Cleveland Clinic Foundation (CCF cohort) from January 1, 2000, through December 31, 2010, and 49 278 patients seen at the Henry Ford Hospital (FIT cohort) from January 1, 1991, through December 31, 2009. All patients were 18 years or older and underwent exercise treadmill testing. Data were analyzed from January 1, 2000, to October 27, 2011, in the CCF cohort and from January 1, 1991, to April 1, 2013, in the FIT cohort.The CCF cohort was divided randomly into derivation and validation samples, and separate risk scores were developed for men and women. Net reclassification, C statistics, and integrated discrimination improvement were used to compare the sex-specific risk scores with other tools that have all-cause mortality as the outcome. Discrimination and calibration were also evaluated with these sex-specific risk scores in the FIT cohort.The CCF cohort included 59 877 patients (59.4% men; 40.5% women) with a median (interquartile range [IQR]) age of 54 (45-63) years and 2521 deaths (4.2%) during a median follow-up of 7 (IQR, 4.1-9.6) years. The FIT cohort included 49 278 patients (52.5% men; 47.4% women) with a median (IQR) age of 54 (46-64) years and 6643 deaths (13.5%) during a median (IQR) follow-up of 10.2 (7-13.4) years. C statistics for the sex-specific risk scores in the CCF validation sample were higher (0.79 in women and 0.81 in men) than C statistics using other tools in women (0.70 for Duke Treadmill Score; 0.74 for Lauer nomogram) and men (0.72 for Duke Treadmill Score; 0.75 for Lauer nomogram). Net reclassification and integrated discrimination improvement were superior with the sex-specific risk scores, mostly owing to correct reclassification of events. The sex-specific risk scores in the FIT cohort demonstrated similar discrimination (C statistic, 0.78 for women and 0.79 for men), and calibration was reasonable.Sex-specific risk scores better estimate mortality in patients undergoing exercise treadmill testing. In particular, these sex-specific risk scores help to identify patients at the highest residual risk in the present era.
A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy.
Authors: E. Seront, S. Rottey, B. Sautois, L. A. D'Hondt, J. R. Canon, J. Vandenbulcke, N. Whenham, J. Goeminne, D. Verhoeven, J. H. Machiels
Journal: Journal of Clinical Oncology (2010)

e15087 Background: The altered expression and activating mutations of the mammalian target of rapamycin (mTOR) pathway, and the subsequent release of angiogenic factors, play a role in transitional cell carcinoma (TCC) invasiveness and metastatic potential. We performed a multi-institutional, single-arm, phase II study with RAD001 (everolimus), an oral inhibitor of mTOR, in patients with palliative TCC. Methods: Patients with locally advanced or metastatic TCC with progressive disease after platinum based chemotherapy received everolimus monotherapy 10 mg/day continuously. A two stage design was used (Simon; a=0.15, b=0.1, P0=10%, P1=25%) meaning that at least two of the first 17 patients enrolled should achieve a stable disease (SD) to allow the study to continue until 37 patients. The primary endpoint was disease control rate (SD, PR, CR) at 8 weeks according to RECIST. Results: 37 patients were included. Presently, the first cohort of 17 patients (M/F: 13/4; median age of 67.1years; ECOG 1/2:15/2) are evaluable for activity. All of them had metastatic disease. 4 patients were not evaluable by imaging at 8 weeks due to rapid clinical PD (2), death (1) or toxicity (1) and were considered in PD as prespecified in the protocol. There was no complete or partial response. SD was found in 3 patients at 8 weeks and was maintained for 234 days in one patient. The main grade 3-4 toxicities were fatigue (4 pts), anemia (2 pts), thrombopenia (2 pts) and hyperglycemia (2 pts). Conclusions: Everolimus monotherapy has modest activity in platinum-refractory TCC with a manageable toxicity profile. After the first step of this study, Everolimus met the efficacy criteria to proceed to the second step of the trial according to the predefined 2-stage Simon design. All the patients have now been included. No significant financial relationships to disclose.
TCT-397 Effect of post-dilatation on device expansion and arterial healing following Everolimus-eluting bioresorbable stent (Absorb BVS) versus durable polymer everolimus-eluting metallic stent (EES) implantation in STEMI patients: substudy of ABSORB STEMI TROFI II
Authors: Kyohei Yamaji, Lorenz Raber, Salvatore Brugaletta, Andres Iñiguez, Lisette Okkels Jensen, Angel Cequier, Sjoerd H. Hofma, Evald Christiansen, Maarten Suttorp, Gerrit-Anne Van Es, Yohei Sotomi, Yoshinobu Onuma, Manel Sabate, Patrick Serruys, Stephan Windecker
Journal: Journal of the American College of Cardiology (2016)
A randomized, split-face, controlled, double-blind, single-centre clinical study: transient addition of a topical corticosteroid to a topical retinoid in patients with acne to reduce initial irritation
Authors: G.C. Coman, A.C. Holliday, S.E. Mazloom, R.N. Chavan, M.S. Kolodney
Journal: British Journal of Dermatology (2017)

Topical retinoids are first line medications in acne treatment but are limited by erythema, scaling, dryness, and initial worsening of acne, which contribute to discontinuation.1 2 We sought a pharmacologic strategy to decrease irritation and quicken the onset of action attempting to increase compliance. Topical corticosteroids (TCS) are commonly used for their anti-inflammatory properties, but are generally avoided on the face to prevent skin atrophy and acne induction.3 We believed TCS could be used on the face in acne patients to reduce the initial irritation from tretinoin without exacerbating acne because topical tretinoin clears oral corticosteroid-induced acne.4 Since irritation is less common after 3-4 weeks, the TCS can be withdrawn within a month.

This article is protected by copyright. All rights reserved.
TCT-659 Correlation of histological findings for cerebral debris to computer tomography measured volume calcium load during transcatheter aortic valve replacement
Authors: Tobias Schmidt, Karl-Heinz Kuck, Peter Wohlmuth, Thomas Thielsen, Dimitry Schewel, Jury Schewel, Hannes Alessandrini, Felix Kreidel, Ralf Bader, Julian Rieck, Lennard Nies, Maria Romero, Elena Ladich, Renu Virmani, Christian Frerker
Journal: Journal of the American College of Cardiology (2016)
Traditional Chinese medicine (TCM) utilization among cancer survivors.
Authors: Chun-Ru Chien, Ya-Chen T. Shih, Yu-Min Liao, Shan-Yu Su
Journal: Journal of Clinical Oncology (2013)

e20604 Background: We investigated the utilization patterns of traditional Chinese medicine (TCM) among general cancer survivors before and after their cancer diagnosis when compared to normal population. Methods: Using population-based claim database, we identified 87249 cancer survivors diagnosed within 2000-2004 and 87,237 matched controls. We obtained information on TCM utilization 2 years before and after their diagnosis. We quantified the utilization of TCM in two ways: initiation (any use in a specific year) and intensity (visit counts per year). Descriptive analysis was applied to explore the trends in initiation and intensity for all cancer and controls as well as each major cancer sites separately. Results: TCM intensity (mean annual visits, with 95%CI) was increased substantially (23%) for general cancer survivors after diagnosis: from 1.58 (1.55-1.61) for 1~2 years before diagnosis to 1.94 (1.9-1.98) for 2 nd years after diagnosis, in contrast to the minor increase (10%) for the control group. For most of the major cancer sites, the initiation rate of TCM among cancer survivors increased before diagnosis then gradually returned to around baseline afterward, whereas the intensity increased gradually after diagnosis. The initiation and intensity for the control groups was relatively stable during the corresponding periods. Conclusions: We found that the initiation of TCM was increased in the pre-diagnostic period and the intensity of TCM gradually increased after diagnosis when compared to normal population. Further research is needed to explore whether TCM, or more broadly CAM, can either serve as a clinical alter or bring additional benefits to these patients.
Online CBT is trialled for children with chronic fatigue syndrome
Authors: Nigel Hawkes
Journal: BMJ (2016)

A UK trial launched on 1 November will seek to establish whether cognitive behavioural therapy (CBT) delivered online is effective in treating chronic fatigue syndrome (CFS) in children.

Esther Crawley, professor of child health at the University of Bristol, hopes to recruit 734 children and adolescents over the next three years to be randomly assigned either to a programme of online CBT already shown to be effective in the Netherlands or to advice on managing activities and sleep.

The consultations will be conducted using Skype and will involve children and their parents. The children will answer questions and keep diaries and will have regular consultations with therapists, usually weekly. A full course will comprise 19 consultations, and Crawley hopes that, after allowing for loss to follow-up, she will have 330 children in each group to …
Pretreatment expectations of side effects from endocrine therapy found to influence occurrence
Authors: Mary Kay Barton
Journal: CA A Cancer Journal for Clinicians (2016)

Key Points A higher expectation of side effects from adjuvant endocrine therapy increased the risk of actual side effects experienced. Adherence was worse in patients with higher expectations of side effects from adjuvant endocrine therapy, and health‐related quality of life was lower.
A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?
Authors: E Troadec, S Dobbelstein, P Bertrand, N Faumont, F Trimoreau, M Touati, J Chauzeix, B Petit, D Bordessoule, J Feuillard, C Bastard, N Gachard
Journal: Leukemia (2016)

A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?